Arima Genomics, founded in 2015 and based in San Diego, specializes in commercial physical and biological research and development. The company leverages 3D genomics to provide comprehensive insights into the sequence, structure, and regulatory landscape of genomes. Their services focus on cancer genomics and human health, aiming to uncover novel biomarkers and therapeutic targets, thereby accelerating the development of new treatments.
Arima Genomics has made significant strides in the field of 3D genomics, contributing valuable data that enhances the understanding of genomic structures and their implications for disease. Their innovative approach has positioned them as a key player in genomic research, impacting both academic and clinical settings. The company's advancements support the discovery of new biomarkers and therapies, driving progress in personalized medicine and improving health outcomes.
